AbSorber
Latest news
-
2010-03-01
AbSorber strengthen its position on the important US market by acquiring NorDiag’s share of Olerup Inc. AbSorber buys the company together with SSP Primers and after the transition will AbSorber own 50 percent of Olerup Inc. and SSP Primers 50 percent. -
2009-12-09
AbSorber receives European patent protection for its transplantation cross match-test XM-ONE® -
2009-07-02
AbSorber AB announced today a new global distribution partner for the transplantation diagnostic product XM-ONE® effective from July 1, 2009. -
2009-05-05
Professor Ron Shapiro, Pittsburgh, PA, discusses the XM-ONE Multicenter Study...
A Tool for enhanced risk assessment
The last decades there has been a substantial increase in short-term and long-term survival of transplanted grafts from both living and diseased donors (1). Nevertheless acute rejection affecting long-term graft survival remains a significant problem. Despite lymphocyte cross-matches, approximately 15-20% of kidneys undergo early rejections (2).
1. Hariharan S et al, N Engl J Med 2000, 342:605-12. 2. Sumitran-Holgersson S and Holgersson J, Current Opinion in Organ Transplantation 2006, 11:425-432. 3. Breimer, M et al, Transplantation 2009, 87(4):549-556.
AbSorber
AbSorber AB is a biotech company focused on developing products that increase the probability of transplantation success. XM-ONE®, the first AbSorber product on the market, is a CE-marked and FDA registered transplantation crossmatch test kit. In contrast to current crossmatch testing, XM-ONE® rapidly detects antibodies specific for endothelial-specific antigens as well as antibodies specific to major transplantation antigens. read more»
Highlighted Meeting
| Date: | May 1-5, 2010 |
| Location: | San Diego, California |
Newsletter
Get information on XM-ONE® and stay tuned with AbSorber through our newsletter.